Health care stocks were falling pre-bell Monday, with The Health Care Select Sector SPDR Fund (XLV) down 0.6% and the iShares Biotechnology ETF (IBB) 1.1% lower.
Regeneron Pharmaceuticals (REGN) shares were down 0.9% after the company said late Friday that the US Food and Drug Administration issued a complete response letter rejecting its request to add extended dosing intervals for Eylea HD injection 8 mg across all approved indications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.